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Results: Median age was 62 years (range: 37-89), 64% females, 86% had a PS 1, 54%/
13% were never/current smokers. Patients had one (44%), two (34%) or more (22%)
prior treatment lines. At diagnosis, patients had EGFR exon 19 deletion (74%), L858R
exon 21 mutation (24%) and concomitant exon 18/ exon 20 mutation (2%). Before Osi
start, T790M was detected in blood (28%) or tumor tissue (72%). Median follow-up
was 15.3 (IQR: 8.6-21.6) months. Overall response rate was 83%, median progression-
free survival 15.1 months (IQR: 6.4-20.1), median overall survival 25.1 months (IQR:
16.7-not reached [NR]) and median treatment duration 18.1 months (IQR: 10.1-23.5).
At data cut off, PD had occurred in 26 patients (52%). There were 73% oligo- vs. 27%
systemic PD. Median treatment duration in patients with oligo-PD was 19.6 vs 6.5
months if systemic PD. The number of progressive lesions in oligo-PD patients were 1
(32%), 2 (37%), 3 (26%), and 5 (5%). Main sites of PD were lung (n¼ 14), bone
(n¼ 10), lymph nodes (n¼ 6), liver and pleura (n¼ 5 each), and brain (n¼ 4). 12
patients with oligo-PD continued treatment with Osi beyond progression, ten of them
after local therapy (8x radiotherapy, 2x surgery). Median time of treatment beyond PD
was 10.7 months in patients with oligo-PD (IQR: 5.7-NR). Analyses of pretreatment
and post-PD tumor tissue from a subset of patients will be presented.
Conclusions: In patients with acquired resistance to Osi, we observed a high rate of extrac-
ranial oligo-PD. Outcomes of patients with oligo-PD were favorable with the majority con-
tinuing Osi in addition to local therapy, supporting the concept of Osi treatment beyond
progression in combination with local therapy of progressing lesions.
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Background: Afatinib is an irreversible ErbB family blocker, which is approved as
monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)
patients with activating EGFR mutations. Here we report the first interim analysis of
the NIS GIDEON, which was initiated to investigate the efficacy and tolerability of
Afatinib in first line treatment in the daily clinical routine in Germany.
Methods: EGFR-mutated NSCLC patients were treated with Afatinib according to label
until progression, death or discontinuation due to patients’ or physicians’ decision.
Efficacy (objective response rate, ORR; disease control rate, DCR and progression-free
survival, PFS) was prospectively assessed by investigators and additional data about tol-
erability under everyday treatment conditions were documented.
Results: A total of 151 pat. were enrolled in the study and received Afatinib treatment.
EGFR mutations comprised exon 19 deletions (Del19, 56.6 %), L858R point mutations
(21.9 %) and uncommon mutations (18.5 %). Median age was 67 years (38-89) with 91
Pat.65 years (60.3%). Pat. started treatment on 40mg/d (72.8 %) Afatinib or< 40mg/d
(25.8 %). Dose reductions during the course of therapy were frequent, 61.8 % with 40mg/d
starting dose and 53.8% with<40mg/d. ORR for the total treated population was 73%
with a DCR of 90 %. ORR was similar according to different subgroups, e.g. mutation type
and age. mPFS at the time of analysis was 12.9 Mon. and in the group of pat.65 years 13.7
Mon. OS date are not mature yet. The most frequent documented AEs were diarrhea and
rash/acne, with 11.6 % of pat. discontinued treatment due to drug related AEs.
Conclusions: Afatinib is a standard therapy for patients with activating EGFR muta-
tions in Germany. The first results of this prospective NIS confirm the robust clinical
data for Afatinib in the clinical routine setting, especially in the elderly population,
which is underrepresented in clinical trials. A starting dose of< 40 mg Afatinib in
selected pat. does not seem to be inferior in terms of efficacy.
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Background: Epidermal growth factor receptor (EGFR) exon 20 insertions are identi-
fied in 4-10% of al EGFR mutations in non-small cell lung cancer (NSCLC) and are
generally associated with primary resistance to first and second generation EGFR tyro-
sine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that
osimertinib exerts antitumor activity in EGFR exon 20 insertion positive NSCLC cell
lines. We report on a cohort of advanced stage NSCLC patients, harboring an EGFR
exon 20 insertion, that was treated with osimertinib.
Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion
were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands.
Data were obtained retrospectively. EGFR mutation status was assessed by next-genera-
tion sequencing. Progression free survival (PFS), disease control rate (DCR) and objec-
tive response rate (ORR) were assessed using RECIST v1.1.
Results: Median age was 63 years (range 35 – 81), 71% was female and median number
of prior systemic treatments was 1 (range 0 – 3). Ten patients (59%) received prior plat-
inum-based chemotherapy, and 2 patients afatinib, one patient experienced stable dis-
ease for 11 months, the other patient showed progression. Among all patients treated
with osimertinib, we observed 1 partial response, 13 patients with stable diseases and 3
with progressive disease as best response (ORR 6%). Two patients were still on osimer-
tinib treatment at the cut-off date. Median PFS was 3.7 months (95% CI: 2.3 – 5.4















1 2 Yes no SD 4.0
2 1 Yes no SD 1.6
3 2 Yes no PR 0.7
4 1 Yes no PR 0.7
5 2 Yes no SD 3.8
6 1 Yes no SD 3.0
7 3 Yes no SD 9.3
8 1 Yes no SD 17.0
9 1 No no SD 3.7
10 1 Yes no SD 17.2
11 0 No no PR 3.1
12 0 No no SD 2.6
13 0 No no SD 6.5
14 3 Yes afatinib (SD) SD 7.9
15 1 No afatinib (PD) PD 1.7
16 0 no no SD 8.3
17 0 no no SD 1.4
EGFR, epidermal growth factor receptor; RECIST: Response Evaluation
Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, pro-
gressive disease; PFS, progression free survival
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Conclusions: Osimertinib has limited antitumor activity in patients with EGFR exon
20 mutated NSCLC, with an ORR of 6%. A subset of patients (35%) seems to derive
benefit from osimertinib treatment with durable disease control for more than five
months.
Legal entity responsible for the study: J. de Langen.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background: An uncommon EGFR-mutant NSCLC is a rare subset of NSCLC.
Prevalence and clinical outcome of this entity remain unclear. Several studies have
reported the benefit of EGFR-tyrosine kinase inhibitor in patients harboring complex
or uncommon EGFR mutations but there are insufficient data to determine the advant-
age of EGFR-TKI over chemotherapy. This study aimed to review the prevalence and
clinical outcome of treatment of uncommon EGFR-mutant patients in real-world
practice.
Methods: We retrospectively reviewed medical records of 681 patients tested for EGFR
mutation NSCLC during 2014-2018 to collect the mutational status and to compare
the survival outcomes between the patients treated with EGFR-TKI and chemotherapy.
Results: At a median follow-up of 19.1 months, 317 (47%) patients were identified
with EGFR-mutant NSCLC. Twenty-eight patients (8.8%) harbored uncommon EGFR
mutations. Of those 28 patients, the most frequent single mutation was exon20 inser-
tion (21%, n¼ 6); 5 were L861Q and 4 were G719X. 13 (46%) patients had compound
mutations: 4 were G719X plus S768I; 4 were de novo T790M plus either L858R or dele-
tion(del)19; 2 were L858R plus del19; 1 was L858R plus Ex20Ins; 1 was del19 plus KRAS
mutation, and 1 with G719X plus E709A was found in squamous cell carcinoma.
History of tobacco use was found in 50% of patients. 100% of male patients with
G719X mutation were smokers. 57% of the 28 patients were treated with EGFR-TKI,
mostly 1st generation, and 29% were treated with chemotherapy alone. The objective
response rate was 56% in the TKI group. Median progression-free survival (PFS) in the
TKI group was 10.2 months. 5-year overall survival (OS) rate was 34%. Patients treated
with TKI had significantly better 5-year OS rate than those who had never received TKI
(54% vs. 17%, 95%CI 1.23-14.66, p log-rank¼ 0.02). The longest OS was 73.6 months
in a patient with del19 plus de novo T790M.
Conclusions: This study demonstrated the benefit of 1st generation EGFR-TKI was
greater than with chemotherapy alone in the patients with uncommon or compound
EGFR mutation NSCLC. Rare EGFR mutations can be detected in squamous cell carci-
noma. There was a high prevalence of smoking among the male patients with G719X-
mutant NSCLC.
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Background: EGFR T790M mutation is the most common acquired mechanism of
resistance in NSCLC patients treated with EGFR-TKI. Alternative mechanisms include
activation of the receptor tyrosine kinases MET or AXL. S49076 is a multi-target inhibi-
tor and a potent ATP-competitive TKI that targets MET, AXL and FGFR1/2/3. Here we
report phase 1 molecular and safety data of resistant patients without the EGFR T790M
mutation that were treated with S49076 combined with gefitinib.
Methods: A dose-escalation of S49076 in combination with gefitinib 250 mg once daily
was conducted using a modified Bayesian Continual Reassessment Method. Toxicity
was evaluated according to Common Terminology Criteria for Adverse Events (AEs),
v4.0. Resistant patients were selected according to a tumor molecular profile including
presence of the activating EGFR mutation, absence of T790M and with at least one of
the following: MET amplification, or MET or AXL overexpression.
Results: The molecular profile screening has been performed in 46 EGFR/T790M-neg-
ative tumour samples. In total, 23/46 met the molecular eligibility criteria: 21 with
MET dysregulation (11 MET amplification, 20 MET overexpression and 4 both MET /
AXL dysregulations), and 2 with AXL overexpression only. Fourteen patients were
treated: 4 received the 500 mg dose and 10 received the 600 mg dose, which was consid-
ered as the recommended dose. Related AEs included diarrhoea, paronychia, asthenia,
nausea, vomiting, ALAT and ASAT increase, anaemia, peripheral oedema and yellow
skin, mostly grade 1-2. One patient experienced a DLT at 600 mg (grade 3 stomatitis); 2
patients experienced 3 serious related AEs (asthenia, atrial fibrillation and diarrhoea).
No grade 4-5 AEs were reported. Concomitant intake of gefitinib did not appear to
modify the S49076 PK profile as compared to previous data. Limited anti-tumour
activity was observed in the 12 evaluable patients: 1 partial response and 9 stable
diseases.
Conclusions: S49076 combined with gefitinib is well tolerated and data are consistent
with the overall safety profile of each drug. The observed frequency of MET dysregula-
tion was comparable to those reported in the literature whereas AXL overexpression
was lower than expected.
Clinical trial identification: EudraCT: 2015-00264631.
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